← Eichor
Study identifier: NCT07644715 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis

Condition: Arrhythmia · Long QT Syndrome · Immune Checkpoint Inhibitor-Related Myocarditis  ·  Sponsor: Groupe Hospitalier Pitie-Salpetriere

PhaseN/A
Planned participants127000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data. The project will standardize heterogeneous ECGs, create the ECGInsight harmonized database, and train interpretable models for life-threatening arrhythmia risk prediction, especially Torsades-de-Pointes/long QT syndrome and immune checkpoint inhibitor (ICI)-induced myocarditis. The project uses existing and ongoing national and international ECG cohorts with de-identified clinical metadata; AI outputs are intended for research/model development and are not used to drive patient care during the study.

This description comes directly from the study's public registry record.

Talk to the study team

Joe-Elie Salem, MD-PhD  ·  0033142178535  ·  joe-elie.salem@aphp.fr

Edi Prifti, PhD  ·  +33 1 48 02 55 20  ·  edi.prifti@ird.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CIC-2503Paris, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07644715